Acupuncture therapy for stable angina pectoris: a systematic review and meta-analysis

Zhihan Chen†, Yitong Wang‡, Bing Xue†, Caijiao Liu†, Sijing Li†, Yulan Ren‡*

Authors’ affiliations:
1 School of Acupuncture Moxibustion and Tuina, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
2 School of Chinese Classics, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.

Email addresses:
Zhihan Chen: czhcoral@hotmail.com
Yitong Wang: wytcdtc@gmail.com
Bing Xue: 17742874351@163.com
Caijiao Liu: lchj07141109@126.com
Sijing Li: lsj169068@163.com
Yulan Ren: ryl@cdutcm.edu.cn

†: Equal contributors.

* Correspondence to: Yulan Ren
Chengdu University of Traditional Chinese Medicine
No.37, Shierqiao Road, Jinniu District, Chengdu, Sichuan, China.
Email address: ryl@cdutcm.edu.cn
Telephone number: +8618908204980
Abstract

Background Stable angina pectoris (SAP) is a common cardiovascular disease, which brings health burden to society. Acupuncture therapy is effective in improving SAP as adjunctive therapy, nevertheless, there were controversies on the effect of acupuncture on disease-affected meridian (DAM), sham acupoints and nonaffected meridian (NAM). This study evaluated the effect of acupuncture on DAM as adjunctive therapy, and the difference in acupuncture on DAM, sham acupoints, and nonaffected meridian NAM.

Methods Thirteen online databases were searched from inception to December 2, 2019. Risk of bias and quality of evidence for outcomes were respectively assessed by the Cochrane risk of bias assessment tool and the GRADE approach. RevMan 5.3 was adopted to conduct meta-analysis.

Results Thirteen RCTs including 1026 participants were included in this study. Acupuncture therapy could be effective in the improvement of angina severity, ECG results, 6-MWT, SAQ results (physical limitation, angina stability, angina frequency, treatment satisfaction, disease perception), anxiety, HRV (LF, LF/HF), ET, CRP, and reduction of nitroglycerin intake. Acupuncture on DAM could be more beneficial than acupuncture on sham acupoints in aspects of angina severity, 6-MWT, SAQ results (angina stability, angina frequency, treatment satisfaction, disease perception). Compared to acupuncture in NAM, acupuncture on DAM could be more effective in SAQ results (angina stability, angina frequency, treatment satisfaction). Moreover, acupuncture on DAM did not increase the risk of dropout and adverse effect.

Conclusions Acupuncture on DAM could effectively improving SAP, and it could be more effective compared with acupuncture on sham acupoints or NAM. However, these conclusions were limited by low-quality of most of included studies.

Registration Open Science Framework registration (DOI: 10.17605/OSF.IO/F9DTW).

Keywords
Acupuncture therapy; stable angina pectoris; systematic review; meta-analysis
Background

Stable angina pectoris (SAP) is defined as a persistent and reproducible chest discomfort usually precipitated by a physical exertion that dissipates upon cessation of such an activity, and SAP is symptomatic manifestation of ischemia heart disease (IHD)[1, 2]. There is high prevalence rate of cardiovascular diseases in the Unite State, Central Europe, North Africa and the Middle East[3]. ‘The top 10 causes of death’ indicated that IHD is the world’s biggest killer, accounting for exceeded 9 million deaths in 2016[4], which brings burden of resource and economy to healthcare systems[5]. Previous studies indicated that around 9 million patients are diagnosed with angina in the Unite State[2], and in China, approximate 3.6 percent of population suffer from angina[6]. Patients with SAP have a high risk of major cardiovascular events[7].

The antianginal therapies of SAP are principally pharmacotherapy (β-blockers, calcium channel blockers, nitrates, etc.)[7, 8], besides, percutaneous coronary intervention (PCI)[9], coronary artery bypass grafting (GABG)[7, 10], acupuncture therapy[11, 12], change of lifestyle (smoking cessation, proper exercise, etc.)[8] are used to improve SAP. Acupuncture has long history for attenuating anginal symptom in China. With the advance of technology, type of acupuncture therapies become various, which includes manual acupuncture (MA), electroacupuncture (EA), acupoint application, laser acupuncture, and so on[13]. Thanks to safety and efficacy of acupuncture therapy, an increasing number of patients are willing to accept it. Previous clinical studies[14, 15] verified that acupuncture is effective in alleviating SAP, and animal experiments[16, 17] showed that acupuncture has the effect in protecting myocardium from ischemic injury. However, previous clinical trials[12, 18-20] came to different conclusions in the difference of effect in acupuncture on disease-affected meridian (DAM), sham acupoints and acupuncture on nonaffected meridian (NAM). The six published meta-analyses[21-26] discussed the effect of acupuncture on all acupoints, not acupuncture on DAM. Considering the importance of acupoint selection in treatment and growing number of randomized controlled trials (RCTs) of acupuncture therapy on DAM for SAP, we conducted this systematic review and meta-analysis. The purpose of this study was to assess (a) the effect and safety of various types of acupuncture therapies on DAM as adjunctive therapy in treating SAP, (b) the difference of therapeutic results in acupuncture therapies on DAM, sham acupoints and NAM.


**Methods**

This study was conducted according to the Cochrane Handbook for Systematic Reviews of Interventions[27] and the findings were reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (PRISMA)[28]. Additionally, this study was registered in Open Science Framework (registration DOI: 10.17605/OSF.IO/F9DTW).

**Literature search strategy**

The following online databases were searched from their inception data to December 2, 2019: PubMed, Cochrane Central Register of Controlled Trials (CENTRAL), Embase, Web of Science, Cumulative Index to Nursing and Allied Health Literature (CINAHL), ProQuest Dissertations and Theses, Allied and Complementary Medicine Database (AMED), OpenGrey, Clinicaltrials.gov, who.int/trialsearch, China National Knowledge Infrastructure (CNKI), China Biology Medicine (CBM), WANFANG Data. The search terms included subject headings and free terms, such as “acupuncture”, “acupoint”, “point”, “angina, stable”, “angina*”, “angor pectoris”, etc. There were no language and publication data restrictions. Special search strategies for different online databases are shown in additional file 1.

**Inclusion and exclusion criteria**

Types of studies: clinical RCTs and quasi-RCTs were included in this study; crossover trials, cluster RCTs, cohort studies, case control studies, case series, case reports were excluded.

Types of participants: male and female participants (aged 18 years or over) who diagnosed with SAP by validated criteria. There were no restrictions on race, country of setting, previous antianginal medications and severity of symptoms. Participants with unstable angina pectoris (UAP) were excluded.

Types of interventions: experimental interventions included all types of acupuncture therapies on DAM combined with basic therapies, such as antianginal medications, health education. Control interventions included simple basic therapies, acupuncture therapies on sham acupuncture combined with basic therapies, acupuncture therapies on NAM combined with basic therapies. Thus, eligible studies must include at least one of the following comparators: (1) DAM group versus wait list group (participants only treated by basic therapies); (2) DAM group versus sham acupuncture group; (3) DAM group versus NAM group.
Type of outcomes measures: the primary outcome was frequency of angina attacks, and the secondary outcomes included severity of angina, the number of participants with changes in electrocardiogram (ECG), 6-minute walk test (6-MWT), nitroglycerin intake, Seattle Angina Questionnaire (SAQ), intensity of anxiety, intensity of depression, heart rate variability (HRV), endothelin (ET), C-reactive protein (CRP), brain natriuretic peptide (BNP), retention of treatment, adverse events.

**Data extraction and quality assessment**

After removed duplicates to trash, two reviewers (ZC and YW) independently screened the search results from online databases by titles and abstracts according to the inclusion and exclusion criteria in EndNote X9. Then, the two reviewers independently screened the search results by full-text. Any disagreements were resolved by the third reviewer (YR). The two reviewers (ZC and YW) independently extracted data from included articles to a self-designed data extraction form, which included title, authors, publication year, type of study, country of setting, sample size, diagnosis criteria, characteristics of participants, details of intervention, duration of SAP, previous antianginal medications, outcome measures, and so on. The two reviewers cross-checked completed data extraction forms. If there were any diversities, the third reviewer (YR) was consulted.

The two reviewers (ZC and YW) independently assessed the risk of bias (selection bias, performance bias, detection bias, attrition bias and reporting bias) by the Cochrane risk of bias assessment tool[27]. All included studies were graded as low risk of bias, high risk of bias, or unclear risk of bias. Any diversities were resolved by the third reviewer (YR). For quality of evidence for outcomes, the two reviewers (ZC and YW) independently assessed it through the GRADE approach[29]. The quality of evidence was rated as high, moderate, low, or very low quality in GRADEprofiller (GRADEpro) 3.6.1. Any controversies were handled by the third reviewer (YR).

**Data synthesis and analysis**

RevMan 5.3 was adopted to conduct meta-analysis of efficacy data. Dichotomous data were analyzed via risk ratios (RRs) with 95% confidence intervals (CIs), and continuous data were analyzed by standardized mean differences (SMDs) or mean differences (MDs) with 95% CIs. When there were no events in all arms, this study was excluded from meta-analysis of RR[27].
When outcomes were measured by different tools, data were summarized as SMDs; when outcomes were measured by same tool, data were summarized as MDs. Heterogeneity was tested by $I^2$ statistic. If $I^2$ statistic $> 50\%$, data analyses were conducted using random-effects model; if $I^2$ statistic $\leq 50\%$, fixed-effect model was adopted to perform data analyses[27]. Sensitivity analyses, which were conducted to explore the potential sources of heterogeneity, were performed by excluding studies with high risk of bias from meta-analysis. On account of the difference in therapeutic effect caused by different types of acupuncture therapies, subgroup analysis was carried out when the number of studies was sufficient. Reporting bias was assessed by funnel plots, if the number of included studies was more than 10[27].

**Results**

**Selected Studies**

A total of 14660 articles were initially identified by online database searches, from which 6455 were duplicates, 7366 were excluded through reading titles and abstracts, 839 were reserved for further assessment. After screening by full-texts, 15 articles were included in this study, of which 4 articles[30-33] belonged to 2 studies. Flow diagram for study selection was showed in Figure 1.

**Characteristics of included studies**

A total thirteen studies with 1026 participants were included in this study, which were published between 2004 to 2019. All studies were conducted in different provinces of China, from which one study[12] was reported in English and the others[18-20, 30-40] were reported in Chinese. The sample size of included studies varied from 20 to 398, all participants were diagnosed by validated criteria. Nine studies[12, 20, 32-38, 40] adopted EA as intervention to improve SAP, three studies[18, 19, 39] adopted MA, one study[30, 31] adopted acupoint application. Control groups included wait list group[12, 20, 30-34, 36-38, 40], sham acupuncture group[12, 20, 32-35, 39], acupoints on the NAM group[12, 18-20, 32-34]. For duration of acupuncture therapy, treat duration lasted from two weeks to one month and treatment sessions varied from 10 times to 60 times. Needle retention of EA and MA ranged from 20 to 30 minutes, each treatment time of acupressure lasted 2 minutes. For outcomes measures, frequency of angina attacks[12, 18, 19, 30-37, 39], severity of angina (thereinto, seven studies[12, 18, 19, 32-34, 37, 39] measured severity of angina by visual analog scale (VAS), two studies[30, 31, 35] did not report measure method), the
number of participants with changes in ECG[30, 31, 36, 40], 6-MWT[12, 32-35, 37], nitroglycerin intake[30-33, 36, 37], SAQ[12, 19, 20, 32-34, 39], intensity of anxiety (six studies[12, 19, 34, 35, 37, 39] all adopted self-rating anxiety scale (SAS) to measure intensity of anxiety), intensity of depression (all studies[12, 19, 34, 35, 37, 39] used self-rating depression scale (SDS)), HRV[12, 19, 40], ET[32, 33, 40], CRP[18, 30, 31], BNP[18], retention[12, 18-20, 32, 33, 35-37, 39, 40], adverse events[12, 18, 19, 30, 31, 36, 40] were reported. Characteristics of included trials were displayed in Table 1.

Risk of Bias Assessment

For random sequence generation, eleven studies[12, 18-20, 30-35, 37-39] were assessed by low risk of bias, thereinto, eight studies[18, 19, 30, 31, 34, 35, 37-39] used random number table, two studies[12, 32, 33] adopted central randomization system, one study[20] adopted statistical software to generate random sequence. The other two studies[36, 40] did not describe randomization method. For allocation concealment, two studies[12, 32, 33] concealed allocation by central randomization system, one study[20] used sequentially numbered, opaque, sealed envelopes, the others[18, 19, 30, 31, 34-40] did not report concealment of allocation. For blinding of participants and personnel, three studies[12, 18, 39] were assessed as ‘low risk of bias’, in which participants were treated in a single treatment room; seven studies[20, 30-33, 36-38, 40] were judged to be at ‘high risk of bias’, the other studies[19, 34, 35] did not report the detailed approach of blinding. For blinding of outcome assessment, outcome assessors were masking to allocation in seven studies[12, 18, 20, 32-35, 37], six studies[19, 30, 31, 36, 38-40] did not report related information. For incomplete outcome data, eleven studies[12, 18-20, 32-38, 40] were judged to be at ‘low risk of bias’, two studies had no enough information and were assessed as ‘unclear risk of bias’. For selective reporting, five studies[12, 18, 19, 37, 39] published protocol in journal or registered in website, the other studies[20, 30-36, 38, 40] had no available protocols. For other bias, eleven studies were judged to be at ‘low risk of bias’, and two studies[20, 32, 33] were assessed as ‘high risk of bias’. Table 2 presented risk of bias summary.

Table 2. Risk of bias of included studies.
Effects of intervention

Quality of evidence for outcomes was presented in Table 3. Figures for following meta-analyses were showed in additional file 2.

Frequency of angina attacks

Six studies compared the effect of DAM group and wait list group and the combined result found no difference in frequency of angina attacks (n=376; MD, -2.21; 95% CI -5.74 to 1.32; p=0.22; heterogeneity: $X^2$=128.96, p<0.00001, I$^2$=96%). Removing four studies with high risk of bias from the meta-analysis did not reduce heterogeneity (n=219; MD, 1.65; 95% CI -6.35 to 9.66; p=0.69; heterogeneity: $X^2$=5.55, p=0.02, I$^2$=82%). In subgroup analysis, EA group and wait list
group had no statistic difference (n=349; MD, -1.26; 95% CI -4.92 to 2.41; p=0.50; heterogeneity: $X^2=121.89$, p<0.00001, $I^2=97%$), however, acupoint application group and wait list group had statistic difference (n=27; MD, -10.38; 95% CI -18.06 to -2.70; p=0.008).

The combined result presented that the effect of DAM group and sham acupuncture group in frequency of angina attacks had no differences (n=288; MD, -0.82; 95% CI -4.90 to 3.26; p=0.69; heterogeneity: $X^2=50.27$, p<0.00001, $I^2=92%$). There was high heterogeneity after removed one study with high risk of bias (n=268; MD, 0.13; 95% CI -3.70 to 3.96; p=0.95; heterogeneity: $X^2=12.76$, p=0.005, $I^2=76%$). In subgroup, EA group and sham acupuncture group had no statistic difference (n=262; MD, -0.55; 95% CI -5.38 to 4.27; p=0.82; heterogeneity: $X^2=47.37$, p<0.00001, $I^2=94%$), heterogeneity did not reduce by removing one study with high risk of bias (n=242; MD, 0.95; 95% CI -3.27 to 5.18; p=0.66; heterogeneity: $X^2=5.97$, p=0.05, $I^2=67%$), MA group and sham acupuncture group had no statistic difference (n=26; MD, -1.92; 95% CI -5.64 to 1.80; p=0.31).

There was no statistic difference between DAM group and NAM group in frequency of angina attacks (n=304; MD, -0.01; 95% CI -2.22 to 2.19; p=0.99; heterogeneity: $X^2=16.31$, p=0.003, $I^2=75%$). Removing of study with high risk of bias cannot decrease heterogeneity to 50% (n=284; MD, 0.39; 95% CI -2.10 to 2.89; p=0.76; heterogeneity: $X^2=9.91$, p=0.02, $I^2=70%$). In subgroup, EA group and NAM group had no statistic difference (n=240; MD, 0.81; 95% CI -2.20 to 3.82; p=0.60; heterogeneity: $X^2=9.96$, p=0.007, $I^2=80%$), after removed study with high risk of bias, the heterogeneity significantly decrease (n=220; MD, 2.40; 95% CI 1.33 to 3.46; p=0.0001; heterogeneity: $X^2=0.11$, p=0.74, $I^2=0%$), MA group and NAM group also had no statistic difference (n=64; MD, -1.30; 95% CI -3.35 to 0.75; p=0.22; heterogeneity: $X^2=0.00$, p=0.95, $I^2=0%$).

**Severity of angina**

Low quality evidence suggested that acupuncture on DAM significantly lessened the severity of angina compared to wait list group (n=296; SMD, -0.49; 95% CI -0.73 to -0.26; p=0.0001; heterogeneity: $X^2=5.81$, p=0.21, $I^2=31%$). Subgroup analysis showed that there were significantly statistic differences between EA group and wait list group (n=269; SMD, -0.44; 95% CI -0.68 to -0.20; p=0.0004; heterogeneity: $X^2=3.44$, p=0.33, $I^2=13%$), in addition, acupoint application significantly improving severity of angina (n=27; SMD, -1.13; 95% CI -1.98 to -0.28; p=0.009).
Meta-analysis showed that acupuncture on DAM significantly attenuated severity of angina compared to sham acupuncture group (n=288; SMD, -0.25; 95% CI -0.48 to -0.01; p=0.04; heterogeneity: $X^2=5.39$, p=0.25, $I^2=26\%$). For subgroup analysis, the effect of EA on DAM was better than EA on sham acupoints in alleviating severity of angina (n=262; SMD, -0.33; 95% CI -0.57 to -0.08; p=0.009; heterogeneity: $X^2=0.35$, p=0.95, $I^2=0\%$), nevertheless, MA on DAM did not significant improve severity of angina compared to MA on sham acupoints (n=26; SMD, 0.63; 95% CI -0.17 to 1.43; p=0.12).

There was no evidence of difference between DAM group and NAM group in severity of angina (n=304; MD, 0.13; 95% CI -0.40 to 0.66; p=0.63; heterogeneity: $X^2=9.40$, p=0.05, $I^2=57\%$).

Moreover, the effect of EA on DAM did not improve severity of angina compared with EA on NAM (n=240; MD, -0.23; 95% CI -0.54 to 0.08; p=0.14; heterogeneity: $X^2=0.18$, p=0.92, $I^2=0\%$), MA on DAM significantly alleviating severity of angina compared with MA on NAM (n=64; MD, 0.94; 95% CI 0.24 to 1.64; p=0.008; heterogeneity: $X^2=0.14$, p=0.71, $I^2=0\%$).

**Number of participants with changes in ECG**

The meta-analysis of four studies showed that there was difference in DAM group and wait list group (n=278; RR, 1.27; 95% CI 1.09 to 1.49; p=0.002; heterogeneity: $X^2=0.86$, p=0.84, $I^2=0\%$).

For subgroup analysis, EA group and wait list group had significantly statistic difference (n=151; RR, 1.25; 95% CI 1.07 to 1.47; p=0.005; heterogeneity: $X^2=0.49$, p=0.78, $I^2=0\%$), acupoint application group and wait list group had no statistic difference (n=27; RR, 1.62; 95% CI 0.70 to 3.73; p=0.26). No study reported number of participants with changes in ECG in sham acupuncture group and NAM group.

**6-MWT**

There was evidence of effect of EA on DAM in 6-MWT as adjunctive therapy (n=269; MD, 19.84; 95% CI 3.84 to 35.83; p=0.02; heterogeneity: $X^2=1.89$, p=0.60, $I^2=0\%$). In the meantime, EA on DAM was found to be more effective than EA in sham acupoints in 6-MWT (n=262; MD, 26.08; 95% CI 10.19 to 41.96; p=0.001; heterogeneity: $X^2=0.17$, p=0.98, $I^2=0\%$). Whereas, there was no difference of difference between EA on DAM and EA on NAM in 6-MWT (n=240; MD, -10.11; 95% CI -26.85 to 6.63; p=0.24; heterogeneity: $X^2=3.35$, p=0.19, $I^2=40\%$).

**Nitroglycerin intake**

DAM group and wait list group had statistic difference in reducing nitroglycerin intake (n=157;
SMD, -0.63; 95% CI -0.95 to -0.30; p=0.0002; heterogeneity: $X^2=3.60, I^2=17\%$). In subgroup analysis, EA was effective in decreasing nitroglycerin intake (n=130; SMD, -0.56; 95% CI -0.91 to -0.20; p=0.002; heterogeneity: $X^2=2.67, p=0.26, I^2=25\%$), acupoint application was also effective in reducing nitroglycerin intake (n=27; SMD, -1.00; 95% CI -1.84 to -0.17; p=0.02). Only one study reported nitroglycerin intake of SAP participants after treatment of EA on DAM or sham acupuncture group (n=20; MD, -2.40; 95% CI -5.15 to 0.35; p=0.09). One study reported nitroglycerin intake in DAM group and NAM group, DAM group and NAM group had no difference in rescue medicine intake (n=20; MD, -1.00; 95% CI -2.57 to 0.57; p=0.21).

SAQ

A total of four studies discussed the difference between DAM group and wait list group in SAQ. The combined results presented that EA on DAM combined basic therapies significantly improved physical limitation (n=299; MD, 2.63; 95% CI 1.19 to 4.07; p=0.0003; heterogeneity: $X^2=1.38, p=0.71, I^2=0\%$), angina stability (n=299; MD, 40.15; 95% CI 27.46 to 52.83; p<0.0001; heterogeneity: $X^2=19.58, p<0.0001, I^2=90\%$), angina frequency (n=299; MD, 8.02; 95% CI 5.69 to 10.35; p<0.00001; heterogeneity: $X^2=0.16, p=0.98, I^2=0\%$), and had higher score in treatment satisfaction (n=299; MD, 17.10; 95% CI 10.51 to 23.68; p<0.00001; heterogeneity: $X^2=11.04, p=0.01, I^2=73\%$) and disease perception (n=299; MD, 4.82; 95% CI 2.23 to 7.42; p=0.0003; heterogeneity: $X^2=1.77, p=0.62, I^2=0\%$) compared to basic therapies. For meta-analysis of angina stability score, removing studies with high risk of bias reduced heterogeneity (n=219; MD, 33.20; 95% CI 28.07 to 38.32; p<0.00001; heterogeneity: $X^2=0.36, p=0.55, I^2=0\%$). For meta-analysis of treatment satisfaction score, removing studies with high risk of bias also influenced heterogeneity (n=219; MD, 12.56; 95% CI 8.79 to 16.33; p<0.00001; heterogeneity: $X^2=0.47, p=0.49, I^2=0\%$). For physical limitation score, DAM group had no statistic difference from sham acupoint group (n=328; MD, 0.82; 95% CI -0.88 to 2.52; p=0.35; heterogeneity: $X^2=7.86, p=0.10, I^2=49\%$); in subgroup analysis, the effect of EA on DAM was not different from that of EA on sham acupoints (n=302; MD, 1.09; 95% CI -0.63 to 2.81; p=0.21; heterogeneity: $X^2=3.05, p=0.38, I^2=2\%$), however, the effect of MA on DAM was better than that of MA on sham acupoints (n=26; MD, -12.52; 95% CI -24.56 to -0.48; p=0.04). In addition, there were differences between DAM group and sham acupuncture group in angina stability (n=328; MD, 16.63; 95% CI 8.15 to 25.10;
p=0.0001; heterogeneity: $X^2=11.52$, p=0.009, $I^2=74\%$), angina frequency (n=328; MD, 5.90; 95% CI 3.73 to 8.08; p<0.00001; heterogeneity: $X^2=7.75$, p=0.10, $I^2=48\%$) and disease perception (n=328; MD, 4.13; 95% CI 1.76 to 6.51; p=0.0006; heterogeneity: $X^2=0.56$, p=0.97, $I^2=0\%$). Compared to EA on sham acupoints, EA on DAM was more effective in improving angina stability (n=302; MD, 20.31; 95% CI 16.46 to 24.16; p<0.00001; heterogeneity: $X^2=1.44$, p=0.49, $I^2=0\%$), angina frequency (n=302; MD, 5.96; 95% CI 4.95 to 14.51; p=0.34), treatment satisfaction (n=302; MD, 2.99; 95% CI -8.81 to 14.79; p=0.62) and disease perception (n=302; MD, 7.93; 95% CI -6.10 to 21.96; p=0.27). For subgroup analysis of EA on DAM in treatment satisfaction, after removed two studies with high risk of bias, heterogeneity was reduced (n=222; MD, 5.71; 95% CI 2.26 to 9.16; p=0.001; heterogeneity: $X^2=0.27$, p=0.97, $I^2=0\%$). The effect of MA on DAM had no difference from that of MA on sham acupoints in angina stability (n=26; MD, -3.94; 95% CI -18.41 to 10.53; p=0.59), angina frequency (n=26; MD, 4.78; 95% CI -4.95 to 14.51; p=0.34), treatment satisfaction (n=26; MD, 2.99; 95% CI -8.81 to 14.79; p=0.62) and disease perception (n=26; MD, 7.93; 95% CI -6.10 to 21.96; p=0.27). For subgroup analysis of EA on DAM in treatment satisfaction, after removed two studies with high risk of bias, heterogeneity was reduced (n=222; MD, 5.71; 95% CI 2.26 to 9.16; p=0.001; heterogeneity: $X^2=0.33$, p=0.97, $I^2=0\%$).

There were no evidences for differences between DAM group and NAM group in physical limitation (n=328; MD, -0.93; 95% CI -2.79 to 0.93; p=0.32; heterogeneity: $X^2=0.54$, p=0.97, $I^2=0\%$) and disease perception (n=328; MD, -0.48; 95% CI -3.39 to 2.42; p=0.74; heterogeneity: $X^2=3.18$, p=0.53, $I^2=0\%$), in subgroup analysis, EA on DAM and EA on NAM had no differences in physical limitation (n=300; MD, -0.90; 95% CI -2.78 to 0.98; p=0.35; heterogeneity: $X^2=0.49$, p=0.92, $I^2=0\%$) and disease perception (n=300; MD, -0.44; 95% CI -3.45 to 2.57; p=0.77; heterogeneity: $X^2=3.17$, p=0.37, $I^2=5\%$), MA on DAM and MA on NAM also had no differences in physical limitation (n=28; MD, -2.38; 95% CI -15.28 to 10.52; p=0.72) and disease perception (n=28; MD, -1.07; 95% CI -12.25 to 10.11; p=0.85). The pooled results showed that DAM group were significantly different from NAM group in angina stability (n=328; MD, 11.05; 95% CI 7.06 to 15.04; p<0.00001; heterogeneity: $X^2=1.70$, p=0.64, $I^2=0\%$), angina frequency (n=328; MD, 3.96; 95% CI 1.94 to 5.99; p=0.0001; heterogeneity: $X^2=1.54$, p=0.82, $I^2=0\%$) and treatment satisfaction (n=328; MD, 3.91; 95% CI 1.25 to 6.56; p=0.004; heterogeneity: $X^2=3.22$, p=0.52,
I²=0%). Subgroup analysis showed that there were differences between EA group and NAM group in angina stability (n=300; MD, 11.27; 95% CI 7.17 to 15.38; p<0.00001; heterogeneity: X²=1.49, p=0.48, I²=0%), angina frequency (n=300; MD, 3.99; 95% CI 1.94 to 6.05; p=0.0001; heterogeneity: X²=1.51, p=0.68, I²=0%) and treatment satisfaction (n=300; MD, 4.41; 95% CI 1.64 to 7.18; p=0.002; heterogeneity: X²=1.60, p=0.66, I²=0%), nevertheless, there were no differences between MA group and NAM group in angina stability (n=28; MD, 7.14; 95% CI -9.95 to 24.23; p=0.41), angina frequency (n=28; MD, 2.86; 95% CI -9.31 to 15.03; p=0.65) and treatment satisfaction (n=28; MD, -2.00; 95% CI -11.48 to 7.48; p=0.68).

Intensity of anxiety

Compared to wait list group, the intensity of anxiety in DAM group was significantly relieving anxiety (n=249; MD, -2.25; 95% CI -4.12 to -0.39; p=0.02; heterogeneity: X²=0.92, p=0.63, I²=0%). There was no evidence of difference in intensity of anxiety between DAM group and sham acupuncture group (n=268; MD, -1.23; 95% CI -2.95 to 0.49; p=0.16; heterogeneity: X²=1.27, p=0.74, I²=0%). The pooled analysis of subgroups showed that EA (n=242; MD, -1.33; 95% CI -3.18 to 0.52; p=0.16; heterogeneity: X²=1.20, p=0.55, I²=0%) and MA (n=26; MD, -0.65; 95% CI -5.29 to 3.99; p=0.78) were not more effective in improving anxiety. DAM group and NAM group had no statistic difference in attenuating anxiety (n=248; MD, -1.07; 95% CI -2.80 to 0.65; p=0.22; heterogeneity: X²=0.27, p=0.87, I²=0%). The combined results in subgroups displayed that EA (n=220; MD, -1.25; 95% CI -3.18 to 0.68; p=0.20; heterogeneity: X²=0.11, p=0.74, I²=0%) and MA (n=28; MD, -0.36; 95% CI -4.25 to 3.53; p=0.86) were not more effective comparing with NAM group.

Intensity of depression

The pooled analysis showed that there was no difference between DAM group and wait list group (n=245; MD, -2.82; 95% CI -6.18 to 0.54; p=0.10; heterogeneity: X²=6.35, p=0.04, I²=68%). Heterogeneity was not reduced by removed one study with high risk of bias (n=215; MD, -4.70; 95% CI -9.61 to 0.21; p=0.06; heterogeneity: X²=2.60, p=0.11, I²=61%). The moderate quality evidence of outcomes showed that DAM group and sham acupuncture group had no significantly statistic difference in intensity of depression (n=268; MD, -1.81; 95% CI -3.71 to 0.09; p=0.06; heterogeneity: X²=2.81, p=0.42, I²=0%). In subgroup analysis, EA on DAM was effective in improving depression comparing with EA on sham acupoints (n=242; MD, -2.55; 95% CI -4.67 to
-0.42; p=0.02; heterogeneity: X²=0.58, p=0.75, I²=0%), MA on DAM was not different from MA on sham acupoints (n=26; MD, 1.03; 95% CI -3.16 to 5.22; p=0.63). The effect of acupuncture therapy on DAM and NAM had no difference in intensity of depression (n=248; MD, -1.14; 95% CI -3.18 to 0.90; p=0.27; heterogeneity: X²=0.28, p=0.87, I²=0%), furthermore, EA (n=220; MD, -1.34; 95% CI -3.71 to 1.02; p=0.27; heterogeneity: X²=0.17, p=0.68, I²=0%) and MA (n=28; MD, -0.54; 95% CI -4.57 to 3.49; p=0.79) at DAM were both different from those at NAM.

**HRV**

DAM group and wait list group had differences in LF (n=126; MD, -48.97; 95% CI -88.90 to -9.04; p=0.02) and LF/HF (n=264; MD, -0.59; 95% CI -0.85 to -0.34; p<0.0001; heterogeneity: X²=0.00, p=0.95, I²=0%), and DAM group and wait list group had no difference in HF (n=264; MD, 67.17; 95% CI -53.02 to 187.37; p=0.27; heterogeneity: X²=14.32, p=0.0002, I²=93%) and SDNN (n=126; MD, 3.40; 95% CI -11.22 to 18.02; p=0.65). DAM group was not different from sham acupuncture group in LF (n=133; MD, -27.30; 95% CI -63.94 to 9.34; p=0.14), HF (n=133; MD, 13.10; 95% CI -0.55 to 26.75; p=0.06), LF/HF (n=133; MD, -0.50; 95% CI -1.04 to 0.04; p=0.07), SDNN (n=133; MD, -11.11; 95% CI -39.71 to 17.49; p=0.45). There were no evidences of differences in LF (n=133; MD, -20.24; 95% CI -52.32 to 11.84; p=0.22), HF (n=133; MD, 10.93; 95% CI -2.47 to 24.33; p=0.11), LF/HF (n=133; MD, -1.93; 95% CI -5.30 to 1.44; p=0.26), SDNN (n=161; MD, -9.47; 95% CI -22.27 to 3.33; p=0.15; heterogeneity: X²=0.50, p=0.48, I²=0%) between DAM group and NAM group.

**ET**

The meta-analysis presented difference between DAM group and wait list group (n=158; MD, -0.67; 95% CI -1.00 to -0.35; p<0.0001; heterogeneity: X²=0.35, p=0.55, I²=0%). DAM group and sham acupuncture group had no significantly statistic difference (n=20; MD, -0.32; 95% CI -2.11 to 1.47; p=0.73). DAM group and NAM group also had no statistic difference (n=20; MD, -1.11; 95% CI -2.97 to 0.75; p=0.24).

**CRP**

The combined result showed that DAM group and wait list group had difference in CRP (n=27; MD, -0.99; 95% CI -1.22 to -0.76; p<0.00001). However, there was no difference between DAM group and NAM group (n=36; MD, -3.50; 95% CI -11.25 to 4.25; p=0.38).

**BNP**
No evidence of difference between DAM group and NAM group was found (n=36; MD, -6.25; 95% CI -47.03 to 34.53; p=0.76).

Retention

DAM group and wait list group had no difference in retention (n=566; RR, 0.99; 95% CI 0.96 to 1.03; p=0.66; heterogeneity: X²=1.14, p=0.98, I²=0%). The combined result showed no difference between DAM group and sham acupuncture group (n=334; RR, 0.97; 95% CI 0.92 to 1.02; p=0.17; heterogeneity: X²=1.81, p=0.77, I²=0%). Subgroup analysis presented that EA group and sham acupuncture group had no difference (n=200; RR, 0.97; 95% CI 0.92 to 1.01; p=0.14; heterogeneity: X²=1.77, p=0.62, I²=0%), MA group and sham acupuncture group also had no difference (n=34; RR, 0.95; 95% CI 0.66 to 1.39; p=0.81). In addition, no evidence showed the difference between DAM group and NAM group (n=378; RR, 0.99; 95% CI 0.95 to 1.03; p=0.61; heterogeneity: X²=0.39, p=0.98, I²=0%), meanwhile, EA at DAM and EA at NAM had no difference (n=278; RR, 0.99; 95% CI 0.93 to 1.04; p=0.58; heterogeneity: X²=0.27, p=0.87, I²=0%), MA at DAM and MA at NAM had no difference (n=100; RR, 1.00; 95% CI 0.95 to 1.06; p=1.00; heterogeneity: X²=0.00, p=1.00, I²=0%).

Safety

The meta-analysis of pooled data showed that there was no difference between DAM group and wait list group (n=218; RR, 0.54; 95% CI 0.05 to 5.51; p=0.60; heterogeneity: X²=2.66, p=0.10, I²=62%). A total of six studies[12, 18, 19, 30, 31, 36, 40] reported adverse effect, thereinto, four study[18, 30, 31, 36, 40] reports concrete data in each group. The study[12] conducted by Zhao et al. included DAM group, sham acupuncture group, NAM group and wait list group. In their study, 16 (5%) participants in acupuncture groups reported adverse effects, and all recovered; and one (1%) participant in wait list group report serious adverse effect. Huang et al.[36] reported that no participant had adverse effect in DAM group, four (4%) participants had adverse effect, meanwhile, all participants remained in the trial. Zhang[40] reported that there was no difference between DAM group and wait list group in adverse effect. In the study of Lan[19], a total of four (14%) participants reported adverse effects, and all participants recovered without treatment. In the studies of Li et al.[30, 31] and Jing[18], no participants reported adverse effect.

Heterogeneity

Considering the high heterogeneity for some outcomes, sensitivity analysis and subgroup analysis
were conducted. Heterogeneity was reduced by the removal of study assessed as ‘high risk of bias’ or subgroup analysis based on different type of acupuncture therapies in most of meta-analysis in this study, but not all meta-analysis for outcomes. In fact, there were clinical heterogeneity caused by stimulation modes, duration, dosages, choice of acupoints, etc. In addition, basic therapies had differences. In ten studies, participants all received antianginal western medications, and the other studies adopted Chinese medicine as basic therapy, namely Danshen dripping pills. On account of the number of included studies, we cannot conduct subgroup analysis on all influence factors and sensitivity analysis in all outcomes.

**Reporting Bias**

Considering the number of included studies was insufficient, funnel plot was not generated by RevMan 5.3.

**Discussion**

This systematic review and meta-analysis included 13 studies involving 1026 participants with SAP. In summary, acupuncture on DAM had certain differences from no acupuncture treatment, acupuncture on sham acupoints, and acupuncture on NAM. For primary outcome, there was no evidence that acupuncture therapies on DAM was more effective than no acupuncture treatment, acupuncture on sham acupoints, and acupuncture on NAM. However, in subgroup analysis, acupoint application on DAM could effectively reduce frequency of angina attacks as adjunctive therapy. The quality of these outcomes was low and very low, thus, we could not come to a firm conclusion.

For secondary outcomes, acupuncture therapies on DAM was effective in attenuating severity of angina, anxiety, improving the results in ECG, 6-MWT, SAQ (physical limitation, angina stability, angina frequency, treatment satisfaction, disease perception), HRV, ET and CRP, reducing nitroglycerin intake. Subgroup analysis suggested that EA could be effective in improving severity of angina, the results in ECG, 6-MWT and SAQ (physical limitation, angina stability, angina frequency, treatment satisfaction, disease perception), reducing nitroglycerin intake; acupoint application could be effective in lessening severity of angina and reducing nitroglycerin intake. Compared to sham acupoints, acupuncture therapies on DAM could be more effective in alleviating severity of angina and improving the results in SAQ (angina stability, angina
frequency, treatment satisfaction, disease perception). Compared with NAM, acupuncture therapies on DAM could be more effective in improving the results in SAQ (angina stability, angina frequency, treatment satisfaction). Moreover, acupuncture therapies did not increase the risk of adverse effect.

In this study, 15 percent of selected studies did not report random sequence generation, 77 percent of selected studies did not describe the approach of allocation concealment, 54 percent of selected studies did not mention blinding of participants, 46 percent of selected studies did not mention blinding of outcome assessment, 15 percent of selected studies did not report completeness of outcome data, 62 percent of selected studies did not publish study protocols. In short, seven (54%) studies were rated as ‘high risk of bias’, five (38%) studies were judged as ‘unclear risk of bias’, and only one (8%) study was assessed as ‘low risk of bias’. Because of quality of outcomes and small number of studies, the conclusions in our study was limited.

Acupuncture has physiologic analgesic effects[41], and our study indicated that acupuncture on DAM could effectively improve SAP. Nevertheless, the mechanisms have not yet comprehensively explained. SAP is relevant to the mismatch between demand and supply of myocardial oxygen[42], which is caused by stable coronary artery plaque when myocardial oxygen consumption increase[43]. Previous studies[44-47] stated that acupuncture on DAM can decrease oxygen demand, infarct size, ventricular arrhythmias, left ventricle dysfunction, and so on. Acupuncture on DAM also has the improvements of myocardial ischemia syndromes in regulating autophagy[48], the expression level of adenosine receptor[49], myocardial enzyme[48], myocardial remodeling[50], microvessel formation[51].

Although we searched international general healthcare databases, regional databases, subject-specific electronic bibliographic databases, citation index database, dissertations and theses database, clinical trials registry platforms, grey literature database without language restriction, we cannot rule out the possibility that there are unpublished studies or studies which are published in other databases. All selected studies were conducted in China. Thus, in consideration of singleness of setting, and difference of compliance in acupuncture therapies and acupuncturists’ professional backgrounds, the applicability of acupuncture therapies in improving SAP was restricted.

This study has several limitations. First, the amount of included studies and sample size in most studies was small, and we cannot assess reporting bias by funnel plot. Secondly, high
heterogeneity in some meta-analysis lower the evidence grade. Third, the low quality of some outcomes limited our confidence in the effect of acupuncture on DAM in SAP. Forth, all studies from a single country limited the applicability of acupuncture in SAP. Six previous studies assessed the effect of acupuncture in treating angina. Chen et al.[22] included participants with all types of angina, however, we both agreed that acupuncture combined with conventional drugs could improve ECG and angina symptoms. Yu et al.[24] also included participants with UAP, not only SAP. They categorized included studies into SAP, UAP, coronary heart disease angina pectoris in subgroup analysis. Their subgroup analysis indicated that acupuncture could effectively improve ECG and reduce the number of participants showing ineffectiveness of SAP relief. Zhang et al.[26] searched electronic database from January 2000 to July 2014 and included participants diagnosed with SAP. They discussed the effect of simple acupuncture therapies, and showed that acupuncture therapies increased clinical effects in angina symptoms and ECG, and we all agreed that acupuncture therapies could reduce nitroglycerin intake. Huang et al.[21] compared the difference between simple acupuncture combined with standard treatment and standard treatment in the outcome of effective rate. And they reached a conclusion that acupuncture therapy had increased markedly effective rate as adjunctive treatment. Although we did not assess the effective rate of acupuncture therapy in SAP, our results showed that acupuncture therapies on DAM could be effective in relieving SAP. Liu et al.[23] evaluated the effect of simple acupuncture and acupuncture combined with medicine and we both produced the results that acupuncture therapy could improve anginal symptoms, ECG results as adjunctive therapy. Their results also pointed out that acupuncture therapy reduced intake rate of nitroglycerin, and our results presented that acupuncture therapy at DAM could decrease consumption of nitroglycerin. Yang et al.[25] searched electronic databases from inception to August 2018, and we both came to same conclusions in the effect of acupuncture therapies in anxiety and depression level, safety compared to wait list group or sham acupuncture group. They included participants in intervention group treated by EA or MA in all acupoints, and we included participants in intervention group treated by various acupuncture therapies on DAM. Due to the differences in inclusion criteria and search time, there were disagreements about whether acupuncture could reduce angina attack frequency, nitroglycerin intake and intensity of angina. The six studies did not discuss the differences of curative effect caused by choice of acupoints.
Conclusions

Acupuncture therapy on DAM could be effective and safe in improving severity of angina, anxiety, ECG results, 6-MWT result, SAQ results, HRV, ET, CRP, and reducing nitroglycerin intake as adjunctive therapy, especially EA and acupoint application. No evidence verified that acupuncture therapy on DAM could reduce angina severity, however, in subgroup analysis, Acupoint application on DAM could reduce frequency of angina attacks. Additionally, acupuncture therapies on DAM had certain differences from acupuncture therapies on sham acupoints or NAM in the effect of improving angina severity and physical function. These results are limited by low quality of most of included studies, thus, strong supporting trials are further needed.

List of abbreviations

SAP: stable angina pectoris; IHD: ischemia heart disease; PCI: percutaneous coronary intervention; GABG: coronary artery bypass grafting; MA: manual acupuncture; EA: electroacupuncture; DAM: disease-affected meridian; NAM: nonaffected meridian; RCT: randomized controlled trial; PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines; CENTRAL: Cochrane Central Register of Controlled Trials; CINAHL: Cumulative Index to Nursing and Allied Health Literature; AMED: Allied and Complementary Medicine Database; CNKI: China National Knowledge Infrastructure; CBM: China Biology Medicine; UAP: unstable angina pectoris; ECG: electrocardiogram; 6-MWT: 6-minute walk test; SAQ: Seattle Angina Questionnaire; HRV: heart rate variability; ET: endothelin; CRP: C-reactive protein; BNP: brain natriuretic peptide; GRADEpro: GRADEpro; RR: risk ratio; CI: confidence interval; SMD: standardized mean difference; MD: mean difference; VAS: visual analog scale; SAS: self-rating anxiety scale; SDS: self-rating depression scale.

Declarations

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.
Availability of data and materials
All data generated or analyzed during this study are included in this published article [and its supplementary information files].

Competing interests
The authors declare that they have no competing interests.

Funding
This study is funded by National Natural Science Foundation of China (grant number: 81873239).

Authors’ contributions
ZC and YW contributed equally to this study. ZC, YW, BX, CL, SL and YR participated in the design of study. ZC, YW and YR performed database searching and screening, data extraction, assessment of the risk of bias and evidence quality. ZC, YW, BX, CL and SL analyzed data. ZC and YW drafted this manuscript and YR revised the manuscript. All authors approved the final manuscript.

Acknowledgements
Not applicable.

References
1. National Library of Medicine. Medical Subject Headings. PubMed. 1998.
   https://www.ncbi.nlm.nih.gov/mesh/?term=stable+angina. Assessed 2 Apr 2020.
2. Balla C, Pavasini R, Ferrari R. Treatment of Angina: Where Are We?. Cardiology 2018;140:52-67.
3. Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, et al. Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association. Circulation 2020;141:e139–e596.
4. World Health Organization. The top 10 causes of death. World Health Organization. 2018.
   https://www.who.int/en/news-room/fact-sheets/detail/the-top-10-causes-of-death. Assessed 2 Apr 2020.
5. Long L, Anderson L, Dewhirst AM, He J, Bridges C, Gandhi M, et al. Exercise-based cardiac rehabilitation for adults with stable angina. Cochrane Database of Systematic Review 2018;2:CD012786.
6. Ma D, Sakai H, Wakabayashi C, Kwon JS, Lee Y, Liu S, et al. The Prevalence and Risk Factor
Control Associated With Noncommunicable Diseases in China, Japan, and Korea. J Epidemiol 2017;568-573.

7. Ohman EM. Chronic Stable Angina. N Engl J Med 2016;374(12):1167-1176.

8. Rousan TA, Mathew ST, Thadani U. Drug Therapy for Stable Angina Pectoris. Drugs 2017;77:265-284.

9. Pursnani S, Korley F, Gopaul R, Kanade P, Chandra N, Shaw RE, et al. Percutaneous Coronary Intervention Versus Optimal Medical Therapy in Stable Coronary Artery Disease: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Circ Cardiovasc Interv 2012;5:476-490.

10. Solomon AJ, Gersh BJ. Management of Chronic Stable Angina: Medical Therapy, Percutaneous Transluminal Coronary Angioplasty, and Coronary Artery Bypass Graft Surgery. Lessons From the Randomized Trials. Ann Intern Med 1998;128:216-223.

11. Ballegaard S, Meyer CN, Trojaborg W. Acupuncture in angina pectoris: does acupuncture have a specific effect?. Journal of Internal Medicine 1991;229:357-362.

12. Zhao L, Li D, Zheng H, Chang X, Cui J, Wang R, et al. Acupuncture as Adjunctive Therapy for Chronic Stable Angina: A Randomized Clinical Trial. JAMA Internal Medicine 2019;E1-E12.

13. Ju ZY, Wang K, Cui HS, Yao Y, Liu SM, Zhou J, et al. Acupuncture for neuropathic pain in adults. Cochrane Database of Systematic Review 2017;12:CD012057.

14. Ballegaard S, Jensen G, Pedersen F, Nissen VH. Acupuncture in severe, stable angina pectoris: a randomized trial. Acta Med Scand 1986;220:307-313.

15. Ballegaard S, Pedersen F, Pietersen A, Nissen VH, Olsen NV. Effects of acupuncture in moderate, stable angina pectoris: a controlled study. Journal of Internal Medicine 1990;227:25-30.

16. Shi L, Fang J, Zhao J, Liu G, Zhao Q, Zhang J, et al. Comparison of the Therapeutic Effects of Acupuncture at PC6 and ST36 for Chronic Myocardial Ischemia. Evid Based Complement Alternat Med 2017:7358059.

17. Ying-Wang, Zhao W, Li D, Xu Y, Li M, Chen J, et al. The Beneficial Effects of Electroacupuncture at PC6 Acupoints (Neiguan) on Myocardial Ischemia in ASIC3 -/- Mice. Journal of Acupuncture and Meridian Studies 2018;11:88-96.
18. Jing M. The Influences of Acupuncture at the Acupoint Selected along the Affected Meridian on the Symptoms and the Serum Level of CRP and BNP of Chronic Stable Angina Pectoris Patients. Master's Thesis, Chengdu University of Traditional of Chinese Medicine 2016.

19. Lan Y. Regulation of acupuncture along meridians on resting-state function of insular in stable angina pectoris management: an fMRI study. PhD Thesis, Chengdu University of Traditional of Chinese Medicine 2016.

20. Yang Z, Zhang N, Sun J, Cui J, Feng L, Liu J, et al. Effects observation of curative about electro-acupuncture points along meridians act on chronic stable angina pectoris via the Seattle Angina Questionnaire. CJTCMP 2019;34:3838-3842.

21. Huang X, Guo S, Li F, Tan X, Cai Q, Wang H, et al. Acupuncture as an Adjunctive Treatment for Angina Due to Coronary Artery Disease: A Meta-Analysis. Med Sci Monit 2019;25:1263-1274.

22. Chen J, Ren Y, Tang Y, Li Z, Liang F. Acupuncture therapy for angina pectoris: a systematic review. Journal of Traditional Chinese Medicine 2012;32(4):494-501.

23. Liu Y, Meng H, Khurwolah MR, Liu J, Tang H, Aa N, et al. Acupuncture therapy for the treatment of stable angina pectoris: An updated meta-analysis of randomized controlled trials. Complementary Therapies in Clinical Practice 2019;34:247-253.

24. Yu C, Ji K, Cao H, Wang Y, Jin HH, Zhang Z, et al. Effectiveness of acupuncture for angina pectoris: a systematic review of randomized controlled trials. BMC Complementary and Alternative Medicine 2015;15:90.

25. Yang M, Sun M, Du T, Long H, Chen J, Liang F, et al. The efficacy of acupuncture for stable angina pectoris: A systematic review and meta-analysis. European of Preventive Cardiology 2019;2047487319876761.

26. Zhang Z, Chen M, Zhang L, Zhang Z, Wu W, Liu J, et al. Meta-analysis of acupuncture therapy for the treatment of stable angina pectoris. Int J Clin Exp Med 2015;8:5112-5120.

27. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration 2011; Available from www.handbook.cochrane.org.

28. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Aloannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate
healthcare interventions: explanation and elaboration. BMJ 2009;339: b2700.

29. Schünemann H, Brožek J, Guyatt G, Oxman A. GRADE Handbook. 2013. http://gdt.guidelinedevelopment.org/app/handbook/handbook.html. Assessed 2 Apr 2020.

30. Li M. Clinical therapeutic effect appreciation of xingbitie transdermal patch on coronary heart disease with stable angina pectoris. Master's Thesis, Liaoning University of Traditional of Chinese Medicine 2008.

31. Li M, Liu Z, Sun Z, Wei J. Clinical study of xingbitie transdermal patch in treating angina pectoris due to coronary heart disease. Information on Traditional Chinese Medicine 2008;25:60-62.

32. Zhang N. Study on the mechanism of clinical effect and stable plaque in chronic stable angina patients treated by acupuncture on disease-affected meridian. Master's Thesis, Guiyang College of Traditional Chinese Medicine 2015.

33. Sun J. Study on clinical effect and vasoactive substances in chronic stable angina patients treated by acupuncture on disease-affected meridian. Master's Thesis, Guiyang College of Traditional Chinese Medicine 2015.

34. Chen L. Targeted Metabolomic Study of Acupuncture Along Meridians for Chronic Stable Angina Pectoris. PhD Thesis, Chengdu University of Traditional of Chinese Medicine 2015.

35. Chen L. Metabonomics study on CSAP treated by acupuncture based on liquid chromatography-mass spectrometry. Master's Thesis, Chengdu University of Traditional of Chinese Medicine 2017.

36. Huang J, Yan J, Chang X, Wang C, Yi S, Lin Y. Clinical observation of electroacupuncture on Neiguan in treating chronic angina pectoris. Journal of TCM University of Hunan 2004;24:53-54.

37. Wang N, Chen H, Lu S, Wang J, Zhang W, Zhu BM. Impacts on neutrophil to lymphocyte ratio in patients of chronic stable angina pectoris treated with acupuncture at Neiguan (PC 6). Chinese Acupuncture & Moxibustion 2015;35:417-421.

38. Xie S, Huang J, Liu Y, Hu W, Liu M, Wang C, et al. Clinical observation on stable angina pectoris with the treatment of acupuncture combined with medicine. CJTCMP 2014;29:2385-2387.

39. Yin B. Explore the acupuncture effects on the amplitude of low frequency fluctuation and
fractional amplitude of low frequency fluctuation in patients with chronic stable angina at PC6 and HT5. Master's Thesis, Chengdu University of Traditional of Chinese Medicine 2018.

40. Zhang L. Clinical observation on stable angina pectoris with the treatment of Danshen dripping pills combined with electroacupuncture. Chinese Primary Health Care 2018;32:77-78.

41. Schlaeger J, Cai HY, Steffen AD, Angulo V, Shroff AR, Briller JE, et al. Acupuncture to Improve Symptoms for Stable Angina: Protocol for a Randomized Controlled Trial. JMIR Res Protoc 2019;8:e14705.

42. Thadani U. Management of Stable Angina - Current Guidelines: A Critical Appraisal. Cardiovasc Drugs Ther 2016;30:419-426.

43. Guarini G, Huqi A, Morrone D, Marzilli M. Pharmacological Agents Targeting Myocardial Metabolism for the Management of Chronic Stable Angina : an Update. Cardiovasc Drugs Ther 2016;30:379-391.

44. Zhou W, Ko Y, Benharash P, Yamakawa K, Ajijola SPatelaOA, Mahajan A. Cardioprotection of electroacupuncture against myocardial ischemia-reperfusion injury by modulation of cardiac norepinephrine release. Am J Physiol Heart Circ Physiol 2012;302:H1818-H1825.

45. Ji C, Song F, Huang G, Wang S, Liu H, Liu S, et al. The Protective Effects of Acupoint Gel Embedding on Rats With Myocardial Ischemia-Reperfusion Injury. Life Sci 2018;211:51-62.

46. Li P, Pitsillides KF, Rendig SV, Pan HL, Longhurst JC. Reversal of Reflex-Induced Myocardial Ischemia by Median Nerve Stimulation. Circulation 1998;97:1186-1194.

47. Huang Y, Lu SF, Hu CJ, Fu SP, Shen WX, Liu WX, et al. Electro-acupuncture at Neiguan Pretreatment Alters Genome-Wide Gene Expressions and Protects Rat Myocardium Against Ischemia-Reperfusion. Molecules 2014;19:16158-16178.

48. Zeng Q, He H, Wang XB, Zhou YQ, Lin HX, Tan ZP, et al. Electroacupuncture Preconditioning Improves Myocardial Infarction Injury via Enhancing AMPK-Dependent Autophagy in Rats. Biomed Res Int 2018:1238175.

49. Dai QF, Gao JH, Xin JJ, Liu Q, Jing XH, Yu XC. The Role of Adenosine A2b Receptor in Mediating the Cardioprotection of Electroacupuncture Pretreatment via Influencing Ca 2+ Key Regulators. Evid Based Complement Alternat Med 2019:6721286.

50. Ma L, Cui B, Shao Y, Ni B, Zhang W, Luo Y, et al. Electroacupuncture Improves Cardiac
Function and Remodeling by Inhibition of Sympathoexcitation in Chronic Heart Failure Rats.

Am J Physiol Heart Circ Physiol 2014;306:H1464-H1471.

51. Fu SP, He SY, Xu B, Hu CJ, Lu SF, Shen WX, et al. Acupuncture Promotes Angiogenesis After Myocardial Ischemia Through H3K9 Acetylation Regulation at VEGF Gene. PLoS One 2014;9:e94604.

**Figure legends**

Figure 1. Flow diagram for study selection.
### Table 1. Characteristics of included trials

| Study ID | Country | Study Type | Sample size | Diagnosis | Intervention: acupoints; duration; needle retention | Age (mean±SD or range) | Sex (n) | Duration of stable angina (mean±SD or range) | Previous antianginal medications | Main outcomes |
|----------|---------|------------|-------------|-----------|--------------------------------------------------|------------------------|---------|---------------------------------------------|-------------------------------|--------------|
| Chen 2015 | China | RCT | 43 | ACC/AHA guidelines updated in 2007  
Guideline for diagnosis and treatment of patients with chronic stable angina | G1 (n=11): electroacupuncture and basic therapy (antianginal medications and health education): acupoints on the DAM; 4 weeks (12 sessions); 30 minutes.  
G2 (n=11): electroacupuncture and basic therapy: acupoints on the NAM; 4 weeks (12 sessions); 30 minutes.  
G3 (n=11): sham acupuncture and basic therapy: sham acupoints; 4 weeks (12 sessions); 30 minutes.  
G4 (n=10): basic therapy: 4 weeks. | 67.8±9.2 years  
64.7±10.2 years  
67.1±8.9 years  
67.4±6.1 years | M: 6  
M: 4  
M: 4  
M: 6 | 6.1±5.1 years  
10.1±12.9 years  
7.3±7.3 years  
11.8±9.4 years | Not mentioned | Frequency of angina attacks; severity of angina; 6-MWT; intensity of anxiety; intensity of depression; SAQ. |
| Chen 2017 | China | RCT | 20 | ACC/AHA guidelines updated in 2007  
Guideline for diagnosis and treatment of patients with chronic stable angina | G1 (n=9): electroacupuncture and basic therapy (antianginal medications and health education): acupoints on the DAM; 4 weeks (12 sessions); 30 minutes.  
G2 (n=11): sham acupuncture and basic therapy: sham acupoints; 4 weeks (12 sessions); 30 minutes. | 68±8.5 years | M: 6  
F: 14 | 6.52±6.38 years | Not mentioned | Frequency of angina attacks; severity of angina; 6-MWT; intensity of anxiety; intensity of depression; retension. |
| Huang et al. 2004 | China | RCT | 80 | Nomenclature and criteria for diagnosis of ischemic heart disease | G1 (n=40): electroacupuncture and basic therapy (Danshen dripping pills): acupoints on the DAM; 4 weeks (24 sessions); 30 minutes.  
G2 (n=40): basic therapy: 4 weeks. | 56±15 years  
57±14 years | M: 22  
M: 21 | 5.3±4.5 years  
5.2±4.3 years | Not mentioned | Frequency of angina attacks; ECG; nitroglycerin intake; retention; adverse events. |
| Jing 2016 | China | RCT | 36 | ACC/AHA guidelines updated in 2007  
Guideline for diagnosis and treatment of patients with chronic stable angina | G1 (n=18): manual acupuncture and basic therapy (antianginal medications and health education): acupoints on the DAM; 2 weeks (10 sessions); 30 minutes.  
G2 (n=18): manual acupuncture and basic therapy: acupoints on the NAM; 2 weeks (10 sessions); 30 minutes. | 66.67±6.28 years  
67.11±5.97 years | M: 8  
M: 7 | 64.72±56.24 months  
54.17±64.43 months | Not mentioned | Frequency of angina attacks; severity of angina; CRP; BNP; retention; adverse events. |
| Lan 2016 | China | RCT | 28 | ACC/AHA guidelines updated in 2007  
Guideline for | G1 (n=14): manual acupuncture and basic therapy (antianginal medications and health education): acupoints on the DAM; 2 weeks (10 sessions); 30 minutes. | 64.85±6.03 years | M: 5  
F: 9 | 57.00±50.25 months | Antipllatelet agents, angiotensin-converting enzyme | Frequency of angina attacks; severity of angina; SAQ; |
| Study                          | Country | Design | Study Size | Intervention                                                                                      | Duration | Age | Sex | Major Outcomes                                                                 |
|--------------------------------|---------|--------|------------|--------------------------------------------------------------------------------------------------|----------|-----|-----|--------------------------------------------------------------------------------|
| Li et al. 2008                  | China   | RCT    | 27         | G2 (n=14): manual acupuncture and basic therapy: acupoints on the NAM; 2 weeks (10 sessions); 30 minutes. | 65.78±7.74 years | M: 8 | F: 6 | inhibitors, angiotensin receptor blockers, β-blockers, statins, nitrates, calcium channel blockers |
| Wang et al. 2015                | China   | RCT    | 30         | G1 (n=17): electroacupuncture and basic therapy (antianginal medications): acupoints on the DAM; 4 weeks (12 sessions); 30 minutes. | 55.36±49.77 months | M: 9 | F: 8 | Not mentioned |
| Xie 2014                        | China   | RCT    | 40         | G1 (n=17): electroacupuncture and basic therapy (Danshen dripping pills): acupoints on the DAM; 4 weeks (24 sessions); 30 minutes. | 65.27±5.97 years | M: 7 | F: 13 | Not mentioned |
| Yang et al. 2019                | China   | RCT    | 120        | G1 (n=30): electroacupuncture and basic therapy (antianginal medications): acupoints on the DAM; 4 weeks (12 sessions); 30 minutes. | 62.33±52.65 months | M: 6 | F: 9 | Nitroglycerin; antiplatelet agents; statins; angiotensin |
| Yin 2018                        | China   | RCT    | 26         | G1 (n=15): manual acupuncture and basic therapy (antianginal medications): acupoints on the DAM; 2 weeks (10 sessions); 30 minutes. | 65.27±5.97 years | M: 6 | F: 9 | Frequency of angina attacks; severity of angina; ECG; nitroglycerin intake; CRP; adverse events. |
| Study                  | Country | Design | Sample Size | Description                                                                                                                                                                                                                               | Age | Gender | Follow-up | Interventions                                                                                          | Outcome Measures                                                                 |
|-----------------------|---------|--------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|--------|-----------|-------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------|
| Zhang 2018            | China   | RCT    | 138         | G1 (n=69): electroacupuncture and basic therapy (Danshen dripping pills): acupoints on the DAM; 4 weeks (24 sessions); 30 minutes.                                                                                                          |     |        | 2-10 years| Not mentioned                                                                                         | Frequency of angina attacks; severity of angina; 6-MWT; nitroglycerin intake; SAQ; ET; retention. |
| Zhang and Sun 2015    | China   | RCT    | 40          | G1 (n=99): electroacupuncture and basic therapy (individualized antianginal medications): acupoints on the DAM; 4 weeks (12 sessions); 30 minutes.                                                                                          |     |        | 36-10 months| β-blockers, aspirin, clopidogrel, statins, angiotensin-converting enzyme inhibitors, calcium channel blockers, long-lasting nitrates | Frequency of angina attacks; severity of angina; 6-MWT; SAQ; MWT; intensity of anxiety; intensity of depression; HRV; retention; adverse events. |
| Zhao et al. 2019      | China   | RCT    | 398         | G1 (n=99): electroacupuncture and basic therapy (individualized antianginal medications): acupoints on the DAM; 4 weeks (12 sessions); 30 minutes.                                                                                          |     |        | 36.20±14.79 months| Not mentioned                                                                                         | Frequency of angina attacks; severity of angina; 6-MWT; SAQ; MWT; intensity of anxiety; intensity of depression; HRV; retention; adverse events. |
| Outcomes                          | Group                        | Number of participants (studies) | Relative effect (95% CI)       | Quality of evidence (GRADE)† |
|----------------------------------|------------------------------|---------------------------------|--------------------------------|------------------------------|
| Frequency of angina attacks      | DAM group versus wait list group | 376 (6 studies)                  | MD -2.21 (-5.74 to 1.32)       | ⊗⊕⊕⊕ very low                 |
|                                  | DAM group versus sham acupuncture group | 288 (5 studies)                  | MD -0.82 (-4.90 to 3.26)       | ⊗⊕⊕ low                      |
|                                  | DAM group versus NAM group    | 304 (5 studies)                  | MD -0.01 (-2.22 to 2.19)       | ⊗⊕⊕ low                      |
| Severity of angina               | DAM group versus wait list group | 296 (5 studies)                  | SMD -0.49 (-0.73 to -0.26)     | ⊗⊕⊕ low                      |
|                                  | DAM group versus sham acupuncture group | 288 (5 studies)                  | SMD -0.25 (-0.48 to -0.01)     | ⊱⊕Moderate                    |
|                                  | DAM group versus NAM group    | 304 (5 studies)                  | MD 0.13 (-0.40 to 0.66)        | ⊱⊕ Moderate                   |
| Number of participants with      | DAM group versus wait list group | 278 (4 studies)                  | RR 1.27 (1.09 to 1.49)         | ⊳⊕⊕ low                      |
| changes in ECG                   | DAM group versus sham acupuncture group | 262 (4 studies)                  | MD 26.08 (10.19 to 41.96)      | ⊳⊕⊕ low                      |
|                                  | DAM group versus NAM group    | 240 (3 studies)                  | MD -10.11 (-26.85 to 6.63)     | ⊳⊕⊕ low                      |
| Nitroglycerin intake             | DAM group versus wait list group | 157 (4 studies)                  | SMD -0.63 (-0.95 to -0.30)     | ⊱⊕⊕ low                      |
|                                  | DAM group versus sham acupuncture group | 20 (1 study)                    | MD -2.40 (-5.15 to 0.35)       | ⊱⊕⊕ very low                 |
| Study                        | Patients | MD (95% CI)       | Effect Size | Level   |
|------------------------------|----------|------------------|-------------|---------|
| **DAM group versus NAM group** |          |                  |             |         |
| (1 study)                    |          |                  | 0.57        | very low|
| **SAQ: physical limitation score** |          |                  |             |         |
| DAM group versus wait list group | (4 studies) | 4.07             |             | low     |
| **SAQ: angina stability score** |          |                  |             |         |
| DAM group versus sham acupuncture group | (5 studies) | 2.52             |             | moderate|
| DAM group versus NAM group | (5 studies) | 0.93             |             | moderate|
| **SAQ: angina frequency score** |          |                  |             |         |
| DAM group versus sham acupuncture group | (5 studies) | 25.10            |             | moderate|
| DAM group versus NAM group | (5 studies) | 15.04            |             | moderate|
| **SAQ: treatment satisfaction score** |          |                  |             |         |
| DAM group versus sham acupuncture group | (5 studies) | 8.08             |             | moderate|
| DAM group versus NAM group | (5 studies) | 5.99             |             | moderate|
| **SAQ: disease perception score** |          |                  |             |         |
| DAM group versus sham acupuncture group | (5 studies) | 12.77            |             | moderate|
| DAM group versus NAM group | (5 studies) | 6.56             |             | moderate|
| **SAQ: physical** |          |                  |             |         |
| DAM group versus wait list group | (4 studies) | 2.63 (1.19 to 4.07) |             | moderate|
| **SAQ: angina frequency score** |          |                  |             |         |
| DAM group versus sham acupuncture group | (5 studies) | 16.63 (8.15 to 25.10) |             | moderate|
| DAM group versus NAM group | (5 studies) | 11.05 (7.06 to 15.04) |             | moderate|

30
| Intensity of anxiety | DAM group versus wait | MD | 95% CI | Effect Size |
|----------------------|-----------------------|----|--------|-------------|
| list group           | 249                   | -2.25 (-4.12 to 0.12) | ⊗⊗⊗ | moderate   |
| DAM group versus sham| 268                   | -1.23 (-2.95 to 0.50) | ⊗⊗⊗ | moderate   |
| acupuncture group    | 248                   | -1.07 (-2.80 to 0.67) | ⊗⊗⊗ | moderate   |

| Intensity of depression | DAM group versus wait | MD | 95% CI | Effect Size |
|-------------------------|-----------------------|----|--------|-------------|
| list group              | 245                   | -2.82 (-6.18 to 0.54) | ⊗⊗⊗ | moderate   |
| DAM group versus sham   | 268                   | -1.81 (-3.71 to 0.10) | ⊗⊗⊗ | moderate   |

| HRV: LF | DAM group versus wait | MD | 95% CI | Effect Size |
|---------|-----------------------|----|--------|-------------|
| list group | 126             | -48.97 (-88.90 to -9.04) | ⊗⊗⊗ | low        |
| DAM group versus sham | 133           | -27.30 (-63.94 to 9.34) | ⊗⊗⊗ | low        |

| HRV: HF | DAM group versus wait | MD | 95% CI | Effect Size |
|---------|-----------------------|----|--------|-------------|
| list group | 264             | 67.17 (-53.02 to 187.37) | ⊗⊗⊗ | very low    |
| DAM group versus sham | 133           | 13.10 (-0.55 to 26.75) | ⊗⊗⊗ | low        |

| HRV: HF | DAM group versus wait | MD | 95% CI | Effect Size |
|---------|-----------------------|----|--------|-------------|
| list group | 264             | 59.59 (-0.85 to -0.34) | ⊗⊗⊗ | low        |
| Comparison                        | Study Count | MD       | 95% CI    | Effect Size |
|----------------------------------|-------------|----------|-----------|-------------|
| DAM group versus sham acupuncture group | 1            | 0.04     |           | moderate    |
| DAM group versus NAM group       | 1           | -5.30 to | -1.04 to  | moderate    |
| HRV: SDNN                        |             |          |           |             |
| DAM group versus wait list group  | 1           | -11.22 to| 11.22 to  |             |
| acupuncture group                |             |          |           |             |
| DAM group versus NAM group       | 2           | -22.27 to| -11.11 to | low         |
| ET                               |             |          |           |             |
| DAM group versus wait list group  | 2           | -1.00 to | -1.00 to  | low         |
| acupuncture group                |             |          |           |             |
| DAM group versus NAM group       |             | -2.97 to | -2.11 to  | low         |
| CRP                              |             |          |           |             |
| DAM group versus wait list group  | 1           | -1.22 to | -1.22 to  | low         |
| acupuncture group                |             |          |           |             |
| DAM group versus NAM group       | 1           | -11.25 to| -11.25 to | low         |
| BNP                              |             |          |           |             |
| DAM group versus NAM group       | 1           | 47.03 to | 47.03 to  | low         |
| Retention                        |             |          |           |             |
| DAM group versus wait list group  | 7           | 1.03     | 1.03 to   | low         |
| acupuncture group                |             |          |           |             |
| DAM group versus NAM group       | 5           | 2.53     | 2.53 to   | low         |
| Adverse effect                   |             |          |           |             |
| DAM group versus wait list group  | 5           | 0.05     | 0.05 to   | low         |
| acupuncture group                |             |          |           |             |
| DAM group versus NAM group       | 5           | 0.95     | 0.95 to   | low         |
GRADE Working Group grades of evidence

High quality: further research is very unlikely to change our confidence in the estimate of effect.

Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

Very low quality: We are very uncertain about the estimate.